

LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.:	APPLICATION NO.:
	15741.004	10/754,547
Sheet 1 of 3	APPLICANT:	
	Longgui WANG et al.	
	FILING DATE:	GROUP:
	January 12, 2004	1614

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CITE NO.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B2	WO 99/62503	12/1999	WIPO	A61K	31/00		
	B3	WO 00/61124	10/2000	WIPO	A61K	31/00		
	B4	WO 00/61555	10/2000	WIPO	A61K	31/404		

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
	C20	Alessi, D. R., et al., "PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo," <i>J Biol Chem</i> , Vol. 270, No. 46, pp. 27489-27494 (1995)
	C21	Baugh et al., "Mechanisms for modulating TNF α in immune and inflammatory disease", <i>Curr Opin Drug Discov Devel</i> , 4 (5):635-650 (2001).
	C22	Beagley et al., "Cells and cytokines in mucosal immunity and inflammation", <i>Gastroenterol Clin North Am</i> , 21 (2):347-366 (June 1992) (Abstract only).
	C23	Boehrer, S., et al., "In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation," <i>Cancer Res</i> , Vol. 62, No. 6, pp. 1768-1775 (2002)
	C24	Buchdunger, E. et al., "Bcr-Abl inhibition as a modality of CML therapeutic," <i>Biochim Biophys Acta</i> , Vol. 1551, No. 1, pp. M11-18 (2001)
	C25	Buolamwini, J.K., "Cell Cycle Molecular Targets in Novel Anticancer Drug Discovery," <i>Curr. Pharm. Design</i> , Vol. 6, pp. 379-392 (2000)
	C26	Cather et al., "Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab", <i>Expert Opin Biol Ther</i> , 3 :361-370 (April 2003) (Abstract only).
	C27	Damien, E. et al., "Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest," <i>Oncogene</i> , Vol. 20, No. 29, pp. 3786-3797 (2001)
	C28	Diab et al., "High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats", <i>J Neuropathol Exp Neurol</i> , 56 (6):641-650 (June 1997) (Abstract only).

EXAMINER PHX/2000958.1	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
DC-382230.1	

LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO:	APPLICATION NO:
	15741.004	10/754,547
	APPLICANT: Longgui WANG et al.	
Sheet 2 of 3	FILING DATE:	GROUP:
	January 12, 2004	1614

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
C29	DiPaola, R.S. et al., "Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer." <i>N Engl J Med</i> , Vol. 339, No., 12, pp. 785-791 (1998)
C30	Druker, B.J. et al., "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome," <i>N Engl J Med</i> , Vol. 344, No. 14, pp. 1038-1042 (2001)
C31	Freitas, J.J. et al., "Walker-256 tumor growth causes oxidative stress in rat brain." <i>J Neurochem</i> , Vol. 77, No. 2, pp. 655-663 (2001)
C32	Frey, R. S. et al., "Effects of genistein on cell proliferation and cell cycle arrest in nonneoplastic human mammary epithelial cells: involvement of Cdc2, p21 ^{wal/cip1} , p27 ^{kip1} , and Cdc25C expression," <i>Biochem Pharmacol</i> , Vol. 61, No. 8, pp. 979-989 (2001)
C33	Furukawa, Y., "Cell cycle control genes and hematopoietic cell differentiation," <i>Leuk Lymphoma</i> , Vol. 43, No. 2, pp. 225-231 (2002)
C34	Gabay, C., "IL-1 trap. Regeneron/Novartis", <i>Curr Opin Investig Drugs</i> , 4(5):593-597 (May 2003) (Abstract only).
C35	Ghezzi et al., "Tumor necrosis factor and motoneuronal degeneration: an open problem", <i>Neuroimmunomodulation</i> , 9(4):178-182 (2001) (Abstract only).
C36	Gianni, L. et al., "Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans," <i>J Clin Oncol</i> , Vol. 13, No. 1, pp. 180-190 (1995)
C37	Girolomoni et al., "Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases", <i>Curr Opin Investig Drugs</i> , 3(11):1590-1595 (November 2002) (Abstract only).
C38	Gray, N. et al., "ATP-site Directed Inhibitors of Cyclin-dependent Kinases," <i>Curr. Medicinal Chem.</i> , Vol. 6, No. 9, pp. 859-875 (1999)
C39	Han, J., "Traditional Chinese medicine and the search for new antineoplastic drugs," <i>J Ethnopharmacol</i> , Vol. 24, No. 1, pp. 1-17 (1988)
C40	Hoessel, R. et al., "Indirubin, the active constituent of a Chinese Antileukaemia medicine, inhibits cyclin-dependent kinases," Macmillan Magazines Ltd., <i>Nature Cell Biology</i> , Vol. 1, pp. 60-67 (1999)
C41	Huizing, M.T. et al., "Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients," <i>J Clin Oncol</i> , Vol. 11, No. 11, pp. 2127-2135 (1993)
C42	Ji, X.J. et al., "Pharmacological studies of meisoindigo: absorption and mechanism of action," <i>Biomed Environ Sci</i> , Vol. 4, No. 3, pp. 332-337 (1991)
C43	Kreis, W. et al., "Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines," <i>Br J Urol</i> , Vol. 79, No. 2, pp. 196-202 (1997)
C44	Leclerc et al., "Indirubins Inhibit Glycogen Synthase Kinase-3 β and DCK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease", <i>J. Biol. Chem.</i> , Vol. 276, No. 1, pp. 251-260 (2001)
C45	Li, C. et al., "The Synthesis, Antileukemic Activity, and Crystal Structures of Indirubin Derivatives," <i>Bull. Chem. Soc. Jpn.</i> , Vol. 69, pp. 1621-1627 (1996)

EXAMINER PHX/2000958.1	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
DC-382230.1	

LIST OF REFERENCES CITED BY APPLICANT Form PTO-1449 <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO:	APPLICATION NO:
	15741.004	10/754,547
	APPLICANT:	
	Longgui WANG et al.	
Sheet 3 of 3	FILING DATE:	GROUP:
	January 12, 2004	1614

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
C46	Li, X.K. et al., "Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells," <i>Mol Pharmacol</i> , Vol. 58, No. 6, pp. 1287-1293 (2000)
C47	Liu, X.M. et al., "Induction of differentiation and down-regulation of c-myc gene expression in ML-1 human myeloblastic leukemia cells by the clinically effective anti-leukemia agent meisoindigo," <i>Biochem Pharmacol</i> , Vol. 51, No. 11, pp. 1545-1551 (1996)
C48	Marko, D. et al., "Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells," <i>Br J Cancer</i> , Vol. 84, No. 2, pp. 283-289 (2001)
C49	Merck Manual of Diagnosis and Therapy, 15 th Edition, pp. 1218-1219 (1987)
C50	Mitani, N. et al., "Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma," <i>Cancer Lett</i> , Vol. 165, No. 1, pp. 35-42 (2001)
C51	Morgan, D.O., "Principles of CDK regulation," <i>Nature</i> , Vol. 374, No. 6518, pp. 131-134 (1995)
C52	Ohtsu, T. et al., "Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion," <i>Clin Cancer Res</i> , Vol. 1, No. 6, pp. 599-606 (1995)
C53	Senderowicz, A.M., "Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies," <i>Leukemia</i> , Vol. 15, No. 1, pp. 1-9 (2001)
C54	Sharifi, N. et al., "Targeted chemotherapy: chronic myelogenous leukemia as a model," <i>J Mol Med</i> , Vol. 80, No. 4, pp. 219-232 (2002)
C55	Steinman, R. A., "Cell cycle regulators and hematopoiesis," <i>Oncogene</i> , Vol. 21, No. 21, pp. 3403-3413 (2002)
C56	Tracy, R. P., "Inflammation, the metabolic syndrome and cardiovascular risk," <i>Int. J. Clin Pract</i> , Suppl 10-17 (March 2003) (Abstract only).
C57	Wang, L.G., et al., "Activation of casein kinase II in ML-1 human myeloblastic leukemia cells requires IGF-1 and transferrin," <i>J Leukoc Biol</i> , Vol. 57, No. 2, pp. 332-334 (1995)
C58	Wicki, A. et al., "The Rho/Rho-kinase and the phosphatidylinositol 3-kinase pathways are essential for spontaneous locomotion of Walker 256 carcinosarcoma cells," <i>Int J Cancer</i> , Vol. 91, No. 6, pp. 763-771 (2001)
C59	Wu-Wong, J. R., et al., "Identification and characterization of A-105972, an antineoplastic agent," <i>Cancer Res</i> , Vol. 61, No. 4, pp. 1486-1492 (2001)
C60	Yamaura, T., et al., "Model for mediastinal lymph node metastasis produced by orthotopic intrapulmonary implantation of lung cancer cells in mice," <i>Hum Cell</i> , Vol. 12, No. 4, pp. 197-204 (1999).

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.J./

EXAMINER PHX/2000958.1 /Donna Jagoe/	DATE CONSIDERED 04/22/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
DC-382230.1	